Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 4 , Pages 479-486 , August 2009

Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4)

  • Nancy A. Thornberry, PhD

      Affiliations

    • Department of Metabolic Disorders, Merck Research Laboratories, P.O. Box 2000, Rahway, NJ 07065, USA
    • ,
  • Baptist Gallwitz, MD (Professor, Doctor)

      Affiliations

    • Department of Medicine IV, Eberhard-Karls-University, Otfried-Müller-Str. 10, 72076 Tübingen, Germany
    • Corresponding Author InformationCorresponding author. Tel.: +49 7071 298 2093; Fax: +49 7071 29 5004.

References 

  1. Mest HJ, Mentlein R. Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes. Diabetologia. 2005;48:616–620
  2. Mentlein R. Dipeptidyl-peptidase IV (CD26)–role in the inactivation of regulatory peptides. Regulatory Peptides. 1999;85:9–24
  3. Gault VA, Parker JC, Harriott P, et al. Evidence that the major degradation product of glucose-dependent insulinotropic polypeptide, GIP(3–42), is a GIP receptor antagonist in vivo. The Journal of Endocrinology. 2002;175:525–533
  4. Knudsen LB, Pridal L. Glucagon-like peptide-1-(9–36) amide is a major metabolite of glucagon-like peptide-1-(7–36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. European Journal of Pharmacology. 1996;318:429–435
  5. De Meester I, Korom S, Van Damme J, et al. CD26, let it cut or cut it down. Immunology Today. 1999;20:367–375
  6. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696–1705
  7. Williams-Herman D, Round E, Swern AS, et al. Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. BMC Endocrine Disorders. 2008;8:14
  8. Lankas GR, Leiting B, Roy RS, et al. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes. 2005;54:2988–2994
  9. Gallwitz B. Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. IDrugs. 2008;11:906–917
  10. Deacon CF. Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes. Current Opinion in Investigational Drugs. 2008;9:402–413
  11. Huttner S, Graefe-Mody EU, Withopf B, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers. Journal of Clinical Pharmacology. 2008;48:1171–1178
  12. Ahren B. Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes. Expert Opinion on Emerging Drugs. 2008;13:593–607
  13. Gallwitz B. Sitagliptin: profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes. Drugs of Today (Barcelona). 2007;43:13–25
  14. Ristic S, Bates PC. Vildagliptin: a novel DPP-4 inhibitor with pancreatic islet enhancement activity for treatment of patients with type 2 diabetes. Drugs of Today (Barcelona). 2006;42:519–531
  15. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serum. European Journal of Biochemistry. 1993;214:829–835
  16. Kieffer TJ, McIntosh CH, Pederson RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology. 1995;136:3585–3596
  17. Vilsboll T, Agerso H, Krarup T, et al. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. The Journal of Clininical Endocrinology an Metabolism. 2003;88:220–224
  18. Holst JJ, Deacon CF. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes. 1998;47:1663–1670
  19. Balkan B, Kwasnik L, Miserendino R, et al. Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7–36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia. 1999;42:1324–1331
  20. Reimer MK, Holst JJ, Ahren B. Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice. European Journal of Endocrinology. 2002;146:717–727
  21. Ahren B, Simonsson E, Larsson H, et al. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care. 2002;25:869–875
  22. Marguet D, Baggio L, Kobayashi T, et al. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proceedings of the National Academy of Sciences of the United States of America. 2000;97:6874–6879
  23. Conarello SL, Li Z, Ronan J, et al. Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proceedings of the National Academy of Sciences of the United States of America. 2003;100:6825–6830
  24. Hansotia T, Baggio LL, Delmeire D, et al. Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. Diabetes. 2004;53:1326–1335
  25. De Meester I, Durinx C, Bal G, et al. Natural substrates of dipeptidyl peptidase IV. Advances in Experimental Medicine and Biology. 2000;477:67–87
  26. Sedo A, Malik R. Dipeptidyl peptidase IV-like molecules: homologous proteins or homologous activities?. Biochimica et Biophysica Acta. 2001;1550:107–116
  27. Abbott CA, Yu DM, Woollatt E, et al. Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8. European Journal of Biochemistry. 2000;267:6140–6150
  28. Ajami K, Abbott CA, McCaughan GW, et al. Dipeptidyl peptidase 9 has two forms, a broad tissue distribution, cytoplasmic localization and DPIV-like peptidase activity. Biochimica et Biophysica Acta. 2004;1679:18–28
  29. Ahren B, Foley JE. The islet enhancer vildagliptin: mechanisms of improved glucose metabolism. International Journal of Clinical Practice. Supplement. 2008;8–14
  30. Pospisilik JA, Martin J, Doty T, et al. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes. 2003;52:741–750
  31. Mu J, Woods J, Zhou YP, et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes. 2006;55:1695–1704
  32. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. New England Journal of Medicine. 2005;353:2643–2653
  33. The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes. 1996;45:1289–1298
  34. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–412
  35. Khaw KT, Wareham N, Luben R, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of european prospective investigation of cancer and nutrition (EPIC-Norfolk). BMJ. 2001;322:15–18
  36. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Archives of Internal Medicine. 2001;161:397–405
  37. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care. 2003;26:881–885
  38. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. New England Journal of Medicine. 2008;358:2545–2559
  39. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. New England Journal of Medicine. 2008;358:2560–2572
  40. Holman RR, Paul SK, Bethel MA, et al. 10-Year follow up of intensive glucose control in type 2 diabetes. New England Journal of medicine. 2008;359:1577–1589
  41. Qi DS, Teng R, Jiang M, et al. Two-year treatment with sitagliptin and initial combination therapy of sitagliptin and metformin provides substantial and durable glycaemic control in patients with type 2 diabetes. Diabetologia. 2008;51(Suppl. 1):Presentation 73

PII: S1521-690X(09)00023-2

doi: 10.1016/j.beem.2009.03.004

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 4 , Pages 479-486 , August 2009

Article Tools

* Image Usage & Resolution